CN101508696A - 2-甲基-5-亚胺基-苯并[d][1,3]噁嗪[5-b]吡唑化合物及其制备方法和用途 - Google Patents
2-甲基-5-亚胺基-苯并[d][1,3]噁嗪[5-b]吡唑化合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN101508696A CN101508696A CNA2009101298163A CN200910129816A CN101508696A CN 101508696 A CN101508696 A CN 101508696A CN A2009101298163 A CNA2009101298163 A CN A2009101298163A CN 200910129816 A CN200910129816 A CN 200910129816A CN 101508696 A CN101508696 A CN 101508696A
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- preparation
- methyl
- compare
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
DPPH浓度(mg/100ml) | 5.360 | 2.680 | 1.072 | 0.536 | 0.268 |
吸收值(A) | 1.160 | 0.538 | 0.198 | 0.093 | 0.046 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101298163A CN101508696B (zh) | 2008-07-18 | 2009-03-20 | 2-甲基-5-亚胺基-苯并[d][1,3]噁嗪[5-b]吡唑化合物及其制备方法和制备药物的用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2008100223146A CN101318968A (zh) | 2008-07-18 | 2008-07-18 | 一种苯并噁嗪并吡唑类及开环化合物 |
CN200810022314.6 | 2008-07-18 | ||
CN2009101298163A CN101508696B (zh) | 2008-07-18 | 2009-03-20 | 2-甲基-5-亚胺基-苯并[d][1,3]噁嗪[5-b]吡唑化合物及其制备方法和制备药物的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101508696A true CN101508696A (zh) | 2009-08-19 |
CN101508696B CN101508696B (zh) | 2011-04-06 |
Family
ID=40179265
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2008100223146A Pending CN101318968A (zh) | 2008-07-18 | 2008-07-18 | 一种苯并噁嗪并吡唑类及开环化合物 |
CN2009101298163A Active CN101508696B (zh) | 2008-07-18 | 2009-03-20 | 2-甲基-5-亚胺基-苯并[d][1,3]噁嗪[5-b]吡唑化合物及其制备方法和制备药物的用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2008100223146A Pending CN101318968A (zh) | 2008-07-18 | 2008-07-18 | 一种苯并噁嗪并吡唑类及开环化合物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US7973036B2 (zh) |
JP (1) | JP5345213B2 (zh) |
CN (2) | CN101318968A (zh) |
WO (2) | WO2010006485A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101966146A (zh) * | 2010-09-15 | 2011-02-09 | 青岛黄海制药有限责任公司 | 一种药物组合物溶液及其制备方法和用途 |
CN111116608A (zh) * | 2020-01-10 | 2020-05-08 | 南京医科大学 | 一类具有自由基清除作用的n-苄基苯胺衍生物及其药物用途 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101318968A (zh) * | 2008-07-18 | 2008-12-10 | 青岛黄海制药有限责任公司 | 一种苯并噁嗪并吡唑类及开环化合物 |
CN101830831B (zh) * | 2010-05-25 | 2013-06-12 | 青岛黄海制药有限责任公司 | 一种制备邻肼基苯甲腈的方法 |
US8522624B2 (en) | 2011-03-02 | 2013-09-03 | Cameron International Corporation | System and method for pressure balancing a flow meter |
CN108912142B (zh) * | 2018-08-08 | 2021-06-18 | 延边大学 | 吡咯并苯并恶嗪酮类化合物及其注射剂和在抗血栓中的用途 |
WO2024050800A1 (zh) * | 2022-09-09 | 2024-03-14 | 南京中瑞药业有限公司 | 一种蛋白磷酸酶激动剂和应用 |
CN117055658B (zh) * | 2023-10-11 | 2024-01-02 | 江苏徕德生物医药有限公司 | 用于泰瑞拉奉结晶生产过程的自适应温度控制系统及方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004091441A (ja) * | 2002-09-04 | 2004-03-25 | Mitsubishi Pharma Corp | ピラゾロン誘導体を含有する経口投与製剤 |
JP2004300153A (ja) * | 2003-03-20 | 2004-10-28 | Kiyoshi Kurokawa | 蛋白修飾物生成抑制剤 |
TW200710091A (en) * | 2005-04-11 | 2007-03-16 | Tibotec Pharm Ltd | (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors |
JPWO2006129524A1 (ja) * | 2005-06-03 | 2008-12-25 | 株式会社レナサイエンス | カルボニル化合物除去材 |
CN101318968A (zh) * | 2008-07-18 | 2008-12-10 | 青岛黄海制药有限责任公司 | 一种苯并噁嗪并吡唑类及开环化合物 |
-
2008
- 2008-07-18 CN CNA2008100223146A patent/CN101318968A/zh active Pending
- 2008-07-25 WO PCT/CN2008/071769 patent/WO2010006485A1/zh active Application Filing
-
2009
- 2009-03-20 JP JP2011517738A patent/JP5345213B2/ja not_active Expired - Fee Related
- 2009-03-20 CN CN2009101298163A patent/CN101508696B/zh active Active
- 2009-03-20 WO PCT/CN2009/070905 patent/WO2010006521A1/zh active Application Filing
- 2009-03-20 US US13/054,674 patent/US7973036B2/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101966146A (zh) * | 2010-09-15 | 2011-02-09 | 青岛黄海制药有限责任公司 | 一种药物组合物溶液及其制备方法和用途 |
CN111116608A (zh) * | 2020-01-10 | 2020-05-08 | 南京医科大学 | 一类具有自由基清除作用的n-苄基苯胺衍生物及其药物用途 |
CN111116608B (zh) * | 2020-01-10 | 2022-02-11 | 南京医科大学 | 一类具有自由基清除作用的n-苄基苯胺衍生物及其药物用途 |
Also Published As
Publication number | Publication date |
---|---|
JP5345213B2 (ja) | 2013-11-20 |
CN101508696B (zh) | 2011-04-06 |
WO2010006485A1 (zh) | 2010-01-21 |
US7973036B2 (en) | 2011-07-05 |
WO2010006521A1 (zh) | 2010-01-21 |
CN101318968A (zh) | 2008-12-10 |
JP2011528323A (ja) | 2011-11-17 |
US20110118247A1 (en) | 2011-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101508696B (zh) | 2-甲基-5-亚胺基-苯并[d][1,3]噁嗪[5-b]吡唑化合物及其制备方法和制备药物的用途 | |
RU2538199C2 (ru) | Наносоединения платины и способы их применения | |
CN102273733B (zh) | 用于滤嘴棒的烟用甜味清凉剂缓释胶丸 | |
CN102241675B (zh) | (1R,3S)-1-(4-羟基-3-甲氧羰基)-1,2,3,4-四氢-β-咔啉-3-甲酰氨基酸衍生物及其制备和应用 | |
CN105418601A (zh) | 四氢黄连碱衍生物及其应用 | |
WO2016112875A2 (zh) | 二联苯衍生物及其应用 | |
CN103360317A (zh) | 双环取代吡唑酮偶氮类衍生物、其制备方法及用途 | |
JP2024506657A (ja) | Irak4分解剤およびその使用 | |
CN100572365C (zh) | 用作抗癫痫药的1,2,4-三唑并[4,3-a]喹啉-1-酮衍生物及其可药用盐 | |
CN101654427B (zh) | 抗凝化合物、组合物及其用途 | |
CN104224691A (zh) | 一种盐酸莫西沙星的外用制剂及其制备方法 | |
KR101776412B1 (ko) | 신규 벤즈이미다졸-루테늄 화합물 및 이를 유효성분으로 함유하는 암질환의 예방 또는 치료용 약학조성물 | |
CN111093661A (zh) | 戊二酰亚胺衍生物用于治疗与细胞因子的异常活性相关的疾病的用途 | |
JP4578576B2 (ja) | ガチフロキサシン含有水性液剤 | |
CN100467480C (zh) | 胆汁酸的硝酸酯衍生物及其医药用途 | |
WO2009123098A1 (ja) | ガチフロキサシン含有水性液剤、その製造方法、および、該水性液剤の低温保存および凍結融解時の沈殿生成を抑制する方法 | |
CN102525896B (zh) | 氢溴酸高乌甲素的药物组合物 | |
CN105439889A (zh) | 一种香兰素胺类新化合物、其制备方法及医药用途 | |
WO2020056974A1 (zh) | 一种泊沙康唑磷酸酯单胆碱盐及其制备方法和用途 | |
WO2020051465A1 (en) | Hybrid amphotericin b derivatives with reduced toxicity | |
CN101654405A (zh) | 抗凝化合物、组合物及其用途 | |
CN101003509A (zh) | 吡硫醇的新的药学上可接受的盐及其制备方法 | |
IL300441A (en) | Amphotericin B hybrid amide histology | |
CN102690264B (zh) | 2-苯基-3-取代咪唑并[1,2-a]吡啶类衍生物及其制备方法 | |
CN104490765A (zh) | 一种黄藤素眼用凝胶剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171201 Address after: No. 420, Zhonghua Road, Qinhuai District, Nanjing, Jiangsu Patentee after: Nanjing Zhongrui Pharmaceutical Co.,Ltd. Address before: 266101 Shandong Province, Qingdao city Laoshan District Four Keyuan Road No. 17 Co-patentee before: Nanjing Zhongrui Pharmaceutical Co.,Ltd. Patentee before: QINGDAO HUANGHAI PHARMACEUTICAL Co.,Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20090819 Assignee: SINOBIOWAY BIOMEDICINE Co.,Ltd. Assignor: Nanjing Zhongrui Pharmaceutical Co.,Ltd. Contract record no.: 2018350000005 Denomination of invention: 2- methyl -5- imino benzo [d][1,3] oxazine [5-b] pyrazole compound and its preparation method and use for preparing medicine Granted publication date: 20110406 License type: Exclusive License Record date: 20180510 |
|
EM01 | Change of recordation of patent licensing contract | ||
EM01 | Change of recordation of patent licensing contract |
Change date: 20230411 Contract record no.: 2018350000005 License type after: Exclusive License License type before: Exclusive License |